Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sirajum Munira

Rheumatology Bel Air, MD Medical Doctor

NPI 1295186153 CMS profile 1502219

510 Upper Chesapeake Dr Ste 413, Bel Air, MD 21014

Open in the dashboard

General payments

$4,272

195 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sirajum Munira of Bel Air, MD is reported in the CMS Open Payments database as having received $4,272 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,784 71
2024 General $1,536 77
2023 General $840 42
2022 General $112 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sirajum Munira
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Sirajum Munira were reported at $1,784. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Sirajum Munira Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $112 $627 $125–$2,303 $149
2023 $840 $741 $145–$2,524 $160
2024 $1,536 $830 $166–$2,660 $164
2025 $1,784 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $908 57 payments
  2. Pfizer Inc. $411 23 payments
  3. Amgen Inc. $408 18 payments
  4. UCB, Inc. $383 17 payments
  5. Janssen Biotech, Inc. $324 7 payments
  6. Novartis Pharmaceuticals Corporation $257 9 payments
  7. Aurinia Pharma U.S., Inc. $212 6 payments
  8. E.R. Squibb & Sons, L.L.C. $162 7 payments
  9. Radius Health, Inc. $146 6 payments
  10. Sobi, Inc $116 1 payment
  11. Other $945 44 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,095 193 payments
  2. Education $177 2 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $597 40 payments
  2. XELJANZ $354 19 payments
  3. TREMFYA $303 6 payments
  4. LUPKYNIS $212 6 payments
  5. SKYRIZI Immunology $207 11 payments
  6. Bimzelx $200 9 payments
  7. SKYRIZI Immunology $183 10 payments
  8. Cimzia $183 8 payments
  9. COMIRNATY $165 9 payments
  10. PAXLOVID $165 9 payments
  11. Other $2,300 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

837

Median for Rheumatology: 1,511

Drug cost

$1,117,445

Median for Rheumatology: $1,139,948

Branded share of claims

39.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 64 $470,084
Humira(Cf) Pen Adalimumab Brand 38 $276,928
Rinvoq Upadacitinib Brand 36 $272,981
Xeljanz Xr Tofacitinib Citrate Brand 13 $73,114
Hydroxychloroquine Sulfate Generic 197 $11,480
Methotrexate Methotrexate Sodium Brand 176 $6,894
Febuxostat Generic 25 $3,153
Prednisone Generic 185 $1,132
Allopurinol Generic 54 $844
Leflunomide Generic 34 $681

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$1,445,835

Of which drugs: $1,300,068

Medicare patients

325

Average age 73

Services billed

97,285

264 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 34%
Diabetes 28%
Depression 26%
Ischemic heart disease 25%
Chronic kidney disease 23%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 11 5,880 $175,153
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 15 5,150 $174,663
Injection, tocilizumab, 1 mg J3262 Office 11 36,691 $172,334
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 13 27,200 $97,607
Injection, romosozumab-aqqg, 1 mg J3111 Office 11 8,400 $71,465
Injection, denosumab, 1 mg J0897 Office 25 2,400 $49,296

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $214
$214 36 —
XELJANZ
  • PFIZER INC. $144
$144 13 —
SKYRIZI
  • AbbVie, Inc. $124
$124 — —
Cimzia
  • UCB, Inc. $111
$111 — 27,200
Tymlos
  • Radius Health, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record